San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Fountain Therapeutics is raising $5,999,999.00 in new funding. Sources indicate as part of senior management President, John Dimos played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Fountain Therapeutics

Fountain Therapeutics was founded with the belief that a future in which we live healthier lives longer is more desirable than one in which we continue to be afflicted by the disease of aging. Fountain Therapeutics is discovering and developing treatments for aging-associated diseases. We have built a transformative model of aging that re-creates many of the complex hallmark features of aging, but in a laboratory dish. We are combining this powerful cellular model with the latest in artificial intelligence and computer vision to develop a disruptive unbiased platform for the identification of novel targets and potential therapeutics. We work toward our vision of a future in which we extend healthy lifespan and slow aging itself.

To learn more about Fountain Therapeutics, visit http://www.fountaintx.com/

Contact:
John Dimos, President
628-264-9053
https://www.linkedin.com/in/jtdimos/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved